CAR-T Meeting 2022 | CAR-T trials and research at UKW
Michael Hudecek
• 2 Feb 2022
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, gives an update of the chimeric antigen receptor T-cell (CAR-T) clinical trials and research conducted at the University Hospital of Würzburg (UKW). Dr Hudecek talks on the ongoing CARAMBA-1 trial evaluating autologous SLAMF7 CAR-Ts in multiple myeloma (NCT04499339), and comments on a novel promising target antigen for CAR-T therapy in acute myeloid leukemia (AML). He also explains that a clinical trial for a CAR-T product for breast cancer and lung cancer will be launched soon. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting in which was held virtually in 2022.
